MaverickX

MaverickX is a biotechnology company focused on developing next-generation conditional T-cell engagers (TCEs) for the treatment of solid tumors. The company was founded by the executive team behind Maverick Therapeutics, which was acquired by Takeda, and continues to innovate in the field of multi-specific biologics. MaverickX's technology is designed to produce therapies that remain inactive in systemic circulation and become potently active only upon entering the tumor microenvironment. This selective activation is intended to overcome the narrow therapeutic index and off-tumor toxicities associated with first-generation T-cell engagers.